Decreased cost and time required for genetic sequencing has increased the acceptance of DTC genetic testing among the consumers. DTC genetic testing companies offer these genetic tests to their consumers through online channels and over-the-counter (OTC) channels, which has made these tests easily accessible to consumers around the globe.

BIS Research healthcare experts have found the direct-to-consumer genetic testing market to be one of the growing markets, which is predicted to grow at a CAGR of 17.30% during the forecast period, 2021-2031. The direct-to-consumer genetic testing market’s growth has been primarily attributed to the major drivers in this market, such as growing number of direct-to-consumer genetic testing, increasing research funding in the field of molecular biology, and increase in awareness and acceptance of personalized medicine on a global level. However, genomic data protection, ethical and social issues, and lack of regulatory standards are some of the factors expected to restrain the market growth.

The market is favored by the increased research activities based on next-generation sequencing-based technologies. The technology has been segmented into targeted analysis, whole genome sequencing, and single nucleotide polymorphisms. The whole genome sequencing segment is expected to grow at the highest CAGR of 17.37% during the forecast period 2021-2031. This increase is mainly attributed to a large number of research and development being conducted due to the COVID-19 pandemic and regulatory approvals gained by key companies for genetic health risks-based tests.

Competitive Landscape

With the increasing consumer awareness and intense market penetration, companies such as 23andme, Inc.,, LLC, and Color Genomics have become pioneers and significant competitors in this market.

Other key players in the market are 24Genetics, Easy DNA, DNAfit, and My Heritage Ltd., among others.

The increased demand for complex and custom sequencing techniques, rising genetic testing services, and growing research to treat and diagnose genetic and infectious diseases have opened opportunities for companies to expand their product portfolios, increase automation facilitation, and develop novel consumer genetics solutions by adopting different strategic approaches. Some of the strategies followed by the contributors are new product launches and enhancements, agreements, collaborations, partnerships, acquisitions, and expansions. For instance, in 2020, Eastern Biotech Life Sciences launched Genoplan, which offers advanced genetic tests analyzing hundreds of medical, health, and well-being categories.

Market Segmentation

• Product Type- Ancestry, Health and Wellness, and Entertainment

• Technology – Targeted Analysis, Single Nucleotide Polymorphisms (SNPs), and Whole Genome Sequencing (WGS)

• Distribution Channel- Online Channel and Over-the-Counter Channel

Regional Segmentation

• North America – U.S., Canada

• Europe– Germany, France, Italy, U.K., Spain, and Rest-of-Europe

• Asia-Pacific – China, Japan, Australia, India, and South Korea

• Latin America – Brazil, Mexico, and Rest-of-the-Latin America

• Rest-of-the-World

Furthermore, established key players in the market should work with governments to organize education and awareness programs for consumers and genetic counselors for effective interpretation of results, providing consumers a sense of empowerment, which will certainly help the growth of the market. Due to the limited awareness among consumers and training among primary physicians or genetic counselors, there are high chances of misinterpretation of results and inappropriate test utilization. Professional support to the consumers will help the consumers to understand better about the outcomes and transform the reach of healthcare to the consumers.

Market Growth Drivers

• Growing Number of Direct-to-Consumer Genetic Tests

• Decreasing Cost of Sequencing

• Increasing Research Funding in the Field of Molecular Biology

• Increase in Awareness and Acceptance of Personalized Medicines on a Global Level

Market Challenges

• Genomic Data Protection

• Uncertain Regulatory Standards for Direct-to-Consumer Genetic Tests

• Ethical and Social Issues

Market Opportunities

• Massive Scope for Adoption of Genomic-Based Medicine in Emerging Nations

• Capitalizing on the High Prevalence of Genetic Disorders

• Growth in Emerging Nations

Key Companies Profiled

23andme Inc., 24Genetics, LLC, Atlas Biomed, Color Genomics, DNAfit, Gene by Gene, Chengdu Twenty-Three Rubik’s Cube Biotechnology Co., Ltd., EasyDNA, Mapmygenome, MyHeritage Ltd., Laboratory Corporation of America Holdings, Myriad Genetics, Inc., Konica Minolta, Inc., XCODE Life.

Get Free Sample Report-

Key Questions Answered in this Report:

• What are the major market drivers, challenges, and opportunities in the global direct-to-consumer genetic testing market?
• What are the key development strategies implemented by the major players in order to sustain in the competitive market?
• Which is the dominant product type developed by the leading and emerging players of direct-to-consumer genetic testing market?
• What are the key technologies that have been used by leading players in the global market for the development of consumer genetic tests?
• How is each segment of the market expected to grow during the forecast period 2021-2031? The segments are:
o product type
o technology
o distribution channel
o geography
• Which companies are anticipated to be highly disruptive in the future, and why?
• What are the regulations for the development of direct-to-consumer genetic testing?

Within the research report, the market is segmented on the basis of product type, technology, distribution channel, and region. Each segment covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

BIS Related Studies

Molecular Diagnostics Market - A Global and Regional Analysis

Global Single Cell Sequencing Market

Global Molecular Diagnostics Point of Care Market